Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Hepatic delivery of RNA interference activators for therapeutic application

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Arbuthnot, P.
  • Ely, A.
  • Weinberg, Marc

publication date

  • April 2009

journal

  • Current Gene Therapy  Journal

abstract

  • Globally, hepatic diseases are an important cause of mortality and morbidity. Harnessing RNA interference (RNAi) to silence pathology-causing genes specifically offers exciting possibilities for improvement of treatment. Nevertheless achieving efficient and safe delivery of RNAi activators remains an important objective before this gene silencing approach realizes its full therapeutic potential. Several viral and non viral vectors (NVVs) are being developed for hepatotropic delivery of synthetic and expressed RNAi activators. Each has advantages and disadvantages that are suited to particular disease conditions. Amongst the viral vectors, recombinant adeno-associated viruses and PEG-modified helper dependent adenoviruses show promise for situations that require intermediate to long term expression of RNAi activators. Recombinant lentiviruses have not been used extensively as hepatotropic RNAi vectors, but are likely to find application where lasting therapeutic silencing is required. NVVs are a particularly important class of vector and are effective for delivery of synthetic RNAi activators to the liver. Preclinical investigations using RNAi-mediated gene silencing to counter persistent hepatitis B virus, hepatitis C virus, hepatocellular carcinoma, hypercholesterolemia and cirrhosis are discussed in this review. Although obstacles remain, vigorous research has given impetus to the field and RNAi-based treatment of liver diseases is likely to become a reality in the near future.

subject areas

  • Adenoviridae
  • Carcinoma, Hepatocellular
  • Gene Silencing
  • Genetic Vectors
  • Humans
  • Hypercholesterolemia
  • Liver
  • Liver Diseases
  • Liver Neoplasms
  • Models, Biological
  • RNA Interference
scroll to property group menus

Research

keywords

  • HBV
  • HCV
  • adeno-associated virus
  • adenovirus
  • cirrhosis
  • liver cancer
  • non viral vector
  • siRNA
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1566-5232

PubMed ID

  • 19355867
scroll to property group menus

Additional Document Info

start page

  • 91

end page

  • 103

volume

  • 9

issue

  • 2

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support